Cargando…
LPIN1 downregulation enhances anticancer activity of the novel HDAC/PI3K dual inhibitor FK‐A11
Phosphatidylinositol‐3 kinase (PI3K) inhibitor and histone deacetylase (HDAC) inhibitor have been developed as potential anticancer drugs. However, the cytotoxicity of PI3K inhibitor or HDAC inhibitor alone is relatively weak. We recently developed a novel HDAC/PI3K dual inhibitor FK‐A11 and confirm...
Autores principales: | Imai, Hiroo, Saijo, Ken, Chikamatsu, Sonoko, Kawamura, Yoshifumi, Ishioka, Chikashi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7894020/ https://www.ncbi.nlm.nih.gov/pubmed/33274548 http://dx.doi.org/10.1111/cas.14759 |
Ejemplares similares
-
In Vitro and in Vivo antitumor activity and the mechanism of siphonodictyal B in human colon cancer cells
por: Chikamatsu, Sonoko, et al.
Publicado: (2019) -
Antitumor activity and pharmacologic characterization of the depsipeptide analog as a novel histone deacetylase/ phosphatidylinositol 3‐kinase dual inhibitor
por: Saijo, Ken, et al.
Publicado: (2017) -
Biochemical, biological and structural properties of romidepsin (FK228) and its analogs as novel HDAC/PI3K dual inhibitors
por: Saijo, Ken, et al.
Publicado: (2015) -
Inhibition of IRAK1/4 enhances the antitumor effect of lenvatinib in anaplastic thyroid cancer cells
por: Kawamura, Yoshifumi, et al.
Publicado: (2021) -
Depth of response may predict clinical outcome in patients with recurrent/metastatic head and neck cancer treated with pembrolizumab-containing regimens
por: Saijo, Ken, et al.
Publicado: (2023)